About Trialwise
Trialwise, Inc. is a woman-owned contract research organization (CRO) founded in 1999. The company specializes in Phase I and Phase II clinical studies. As a boutique CRO, Trialwise functions as an extension of a sponsor’s organization to ensure the clinical trial process is managed expertly and efficiently without compromising quality, accuracy, or adherence to protocol and regulatory compliance. 

About SRI International
SRI International is an independent nonprofit research institute headquartered in Menlo Park, California, with a rich history of supporting government and industry. For more than 75 years, SRI International has collaborated across technical and scientific disciplines to discover and develop groundbreaking products and technologies and bring innovations and ideas to the marketplace.

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93020D00011.

The total costs of this program are financed with Federal money; this program is currently funded in the amount of $3,097,464; none of the costs of this program will be financed by nongovernmental sources.

FOSTER CITY, CA, August 16, 2023 — Trialwise, Inc. is proud to be a CRO partner of SRI International in developing an oral treatment for internal radioactive contamination. SRI International has engaged Trialwise to provide clinical operations, data management, biostatistics, and medical writing services in support of the Phase 1 first-in-human clinical trial of the drug, named HOPO 14-1, that has captured the media’s attention.

The study to test the safety and tolerability of HOPO 14-1 was recently featured in National Geographic and republished on the EU Energy Platform.

Recent media coverage of HOPO 14-1 includes:

Trialwise Supports SRI International Phase 1 Study